Bioprocessing Patents: Top Companies & Filing Trends 2026
- Leadership is real but not dominant. the top 5 assignees together hold 18.4% of all 15,247 records in scope, and the top 10 hold 27.0% — concentrated, but with a long tail of active filers behind them.
- Filing has cooled from its 2020 peak. annual filings hit 958 in 2020, and from 2021 (792) to 2024 (488) — the last complete year — volume fell 38%, though 2025-2026 figures are still filling in due to publication lag.
- Microorganism and protein claims dominate the class map. C12N (microorganisms & genetic engineering) touches 53.6% of records and C07K (peptides & proteins) touches 34.1%, leaving bioreactor hardware (C12M, 14.3%) comparatively open.
Filing growth compares 2021 (792 records) with 2024 (488) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 15,247 records in scope (CR5), not by the ranked leaders only.
What the bioprocessing patent record actually shows
Bioprocessing sits at the intersection of cell engineering and industrial production: claims range from gene constructs and host strain modification to fermentation conditions and downstream product recovery. The search scope behind this page pulls 15,247 published records filed or published between 2015 and the 2026 cut-off, indexed against both bioprocessing-specific terms and the operational vocabulary of culture conditions, metabolite production and cell growth.
Because a single filing can carry several IPC classes, the technology composition below adds up to more than the record total — that is expected, and it reflects how densely a typical bioprocessing filing is classified rather than any double-counting. Patent families, not raw document counts, are the fairer unit for comparing filers, since families neutralise aggressive continuation practice and multi-jurisdiction refiling.
Filing trend and technology composition
Two views of the same 15,247-record dataset: how filing volume has moved year over year, and which IPC subclasses carry the claim density.
Filing trend, 2017-2026
Filings rose to a peak of 958 in 2020, then eased; the 2021-to-2024 span (792 to 488, a 38% decline) is the last window that publication lag has fully settled, so read 2025-2026 as still filling in rather than as a continued drop.
Technology composition by IPC subclass
C12N (microorganisms & genetic engineering) and C07K (peptides & proteins) anchor the field at 53.6% and 34.1% of records respectively; A61K (medicinal preparations, 30.6%) and C12P (fermentation & enzymatic synthesis, 29.9%) follow closely, while C12M (bioreactors & apparatus, 14.3%) and C12Q (enzyme/DNA measurement, 6.2%) sit further down the density curve.
Shares are the percentage of the 15,247 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bioprocessing Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about bioprocessing patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe records that define the citation graph
A bioprocessing system and method (US20240052291A1)
Filed by Cellularevolution Ltd and published 2024-02-15, this filing describes a continuous bioprocessing system for adherent cells built around a cell growth chamber, a cell trap with a dedicated outlet, and a fluid flow system that switches between a growth mode and a harvest mode.The claim scope centres on the switchable fluid-flow architecture rather than on any specific cell line or media formulation, which is what makes it relevant to continuous-culture equipment design broadly.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US5731168A | Method for making heteromultimeric polypeptides | 6,503 |
| 2 | US5837458A | Methods and compositions for cellular and metabolic engineering | 4,095 |
| 3 | WO1996027011A1 | A method for making heteromultimeric polypeptides | 3,965 |
| 4 | US20040110704A1 | Cells of which genome is modified | 3,403 |
| 5 | WO1999022764A1 | Methods and compositions comprising glycoprotein glycoforms | 3,359 |
| 6 | US20030115614A1 | Antibody composition-producing cell | 3,303 |
| 7 | WO1998058964A1 | Methods and compositions for galactosylated glycoproteins | 3,267 |
| 8 | US20040132140A1 | Production process for antibody composition | 2,989 |
| 9 | WO2003084570A1 | DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM Fcϝ RIIIa POLYMORPHISM | 2,595 |
| 10 | EP1176195A1 | Method for controlling the activity of immunologically functional molecule | 2,188 |
Citation counts inside this corpus skew toward older filings by construction — treat them as a measure of influence on later filers, not as a signal of current commercial importance.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns stand out once the ranking, the trend and the class map are read together.
Leadership without lock-up
The top 5 assignees hold 18.4% of all records in scope and the top 10 hold 27.0% — enough to show a clear leadership tier, but far short of a closed field. Below the ranked leaders sits a long tail of single- and few-filing entrants, which is where most freedom-to-operate analysis actually has to happen.
Past-peak, not collapsing
Annual filings peaked at 958 in 2020 and fell from 792 in 2021 to 488 in 2024, a 38% decline over that complete three-year window. Because publication lags filing by roughly 18 months, the apparent drop in 2025-2026 numbers should not be read as continued decline until later data cuts confirm it.
Genetic engineering claims crowd the core
Over half of all records touch C12N (microorganisms & genetic engineering), and a third touch C07K (peptides & proteins). Bioreactor hardware and apparatus claims under C12M appear in only 14.3% of records, suggesting the equipment side of bioprocessing carries less claim density than the biological side.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bioprocessing patent landscape, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| Omeros Corp | University of Leicester | 219 |
| Massachusetts Institute of Technology | Broad Institute Inc | 102 |
| Genomatica Inc | BURGARD ANTHONY P | 50 |
| Genentech | F. Hoffmann-La Roche AG | 50 |
| Bristol Myers Squibb Co | FEDER JOHN N | 45 |
| Genomatica Inc | OSTERHOUT ROBIN E | 39 |
| Genomatica Inc | PHARKYA PRITI | 38 |
| Bristol Myers Squibb Co | CHEN JIAN | 36 |
The strongest co-assignee pairing in this dataset links a therapeutics developer with a university partner at 219 shared filings, well ahead of the next academic pairing at 102 — a sign that some of the deepest bioprocessing IP already sits inside joint research agreements rather than single-owner portfolios.
Who is filing, and who has slowed down
The assignee ranking spans 100 companies drawn from the full 15,247-record dataset. The leader holds 886 records, with fifth place at 391 and tenth place at 233 — a steep drop-off that flattens quickly into a long tail.
A clear but not overwhelming leader
The top assignee's 886 records are more than double the fifth-place total of 391, marking a genuine leadership gap at the very top of the ranking even though the combined top 5 share of all records is only 18.4%.
A fast-flattening curve
By tenth place, holdings have dropped to 233 records — still substantial, but the curve from first to tenth flattens quickly, and the top 10 combined account for 27.0% of all records rather than a dominant majority.
Several established filers have gone quiet
Recent-year momentum figures show multiple ranked assignees posting steep YoY declines, some down to zero filings in the latest year. Given the 18-month publication lag, some of this is measurement artefact rather than an actual pullback, but it is worth checking directly with any target company before assuming continued activity.
| Assignee | Recent year | YoY |
|---|---|---|
| Genentech | 1 | 0% |
| Codexis Inc | 1 | -80% |
| Amgen Inc | 1 | -92% |
| Genomatica Inc | 0 | -100% |
| Bristol Myers Squibb Co | 0 | — |
| Regeneron Pharmaceuticals Inc | 0 | -100% |
| Massachusetts Institute of Technology | 0 | -100% |
| Omeros Corp | 0 | — |
Turning the landscape into a filing decision
The trend and class data point to where claim space is dense and where it is not — the next step is testing a specific claim idea against that map.
Check freedom-to-operate against the dense classes
C12N and C07K carry the highest claim density in this field; any new filing touching genetic engineering or protein claims should be checked against the ranked leaders' portfolios first.
Explore claim clustering in EurekaTrack the assignees that have gone quiet
Several ranked leaders show sharp YoY declines that may reflect strategy shifts, M&A, or simply publication lag rather than a real exit from the field.
Monitor assignee activity in EurekaTest white space before drafting claims
Bioreactor hardware and downstream recovery automation show thinner filing density than the biological core, which may leave room for a defensible first claim.
Run a white space search in EurekaCommon questions about the bioprocessing patent landscape
The assignee ranking behind this dataset spans 100 companies, with the leading assignee holding 886 records against a fifth-place total of 391 and a tenth-place total of 233. The top 5 assignees combined hold 18.4% of all 15,247 records in scope, and the top 10 hold 27.0% — a clear leadership tier, but not a closed field, since the remaining 73% of records are spread across a long tail of smaller filers. Anyone assessing competitive position should look at both the leader gap and the depth of that tail before concluding the space is locked up.
Filing volume peaked at 958 in 2020 and has since eased, falling from 792 in 2021 to 488 in 2024 — a 38% decline over that three-year span, which is the most recent window that can be treated as complete. Numbers for 2025 and 2026 appear lower still, but that is expected: publication typically lags actual filing by around 18 months, so the most recent one to two years always understate true activity. Treat the 2021-2024 trend as the reliable read and wait for later data cuts before calling anything past that a slowdown.
Microorganism and genetic engineering claims under IPC class C12N appear in 53.6% of all 15,247 records, making it the single densest class in the field, followed by peptide and protein claims under C07K at 34.1%. Medicinal preparations (A61K, 30.6%) and fermentation and enzymatic synthesis (C12P, 29.9%) are close behind, while bioreactor and apparatus claims (C12M) sit at a comparatively lower 14.3%. Because a single filing often carries several classes, these figures add up to more than 100% of records and should be read as claim density per class, not as mutually exclusive shares.
Relative to the dense biological core, bioreactor hardware and fluid-handling systems (C12M, 14.3% of records) and enzyme/DNA measurement techniques (C12Q, 6.2%) show noticeably thinner filing density than genetic engineering or protein claims. That gap suggests more room to claim specific equipment mechanics, continuous-processing hardware, or in-line monitoring approaches without running into as dense a prior art thicket. Any white-space claim should still be checked against the ranked leaders' specific filings before drafting, since density figures describe a class overall, not any single applicant's coverage.
It sits in the middle: not dominated by one player, but not fragmented either. The leading assignee's 886 records are more than double the fifth-place count of 391, showing a real gap at the top, yet the top 5 and top 10 together account for only 18.4% and 27.0% of all 15,247 records respectively. That leaves the majority of filing activity distributed across the remaining ranked assignees and an unranked tail, which is typical for a field built on both platform biology (genetic engineering, fermentation) and application-specific therapeutics filings.
Research Bioprocessing Patent Landscape in depth with Eureka
Go past this page: query the whole bioprocessing patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.